In Tel Aviv, Israel, on December 24, 2025, Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) revealed that S&P Global Ratings has boosted Teva’s long-term issuer credit rating to ‘BB+’ from ‘BB’, maintaining a stable outlook. Moody's Ratings Agency also affirmed Teva's B1a rating and changed the outlook to positive from stable. These developments signify a notable advancement for Teva in its pursuit of attaining investment-grade standing.